TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis

BMJ Open

Volumn 2, Issue 5, 2012, Pages

  Khatamianfar, Vida ^a   Valiyeva, Fatma ^a   Rennie, Paul S ^b   Lu, Wei Yang ^c   Yang, Burton B ^d   Bauman, Glenn S ^a   Moussa, Madeleine ^a   Xuan, Jim W ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TRIM59; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CARCINOGENESIS; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; EMBRYO; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; SKIN CARCINOMA; TISSUE MICROARRAY; TONGUE CARCINOMA; TRIM59 GENE; UPREGULATION;

EID: 84869773057     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001410     Document Type: Article

References (30)

1. Ozato K, Shin DM, Chang TH, et al. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008;8:849-50.
2. James LC, Keeble AH, Khan Z, et al. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA 2007;104:6200-5.
3. Keeble AH, Khan Z, Forster A, et al. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA 2008;105:6045-50.
4. Si Z, Vandegraaff N, O'hUigin CS, et al. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci USA 2006;103:7454-9.
5. Ellis J, Hotta A, Rastegar M. Retrovirus silencing by an epigenetic TRIM. Cell 2007;131:13-14.
6. Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007;446:916-20.
7. Wolf D, Goff SP. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 2007;131:46-57.
8. Yap MW, Nisole S, Lynch C, et al. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004;101:10786-91.
9. Short KM, Cox TC. Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J Biol Chem 2006;281:8970-80.
10. Lerner M, Corcoran M, Cepeda D, et al. The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD. Mol Biol Cell 2007;18:1670-82.
11. Balastik M, Ferraguti F, Pires-da SA, et al. Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proc Natl Acad Sci USA 2008;105:12016-21.
12. Schwamborn JC, Berezikov E, Knoblich JA. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell 2009;136:913-25.
13. Wang L, Heidt DG, Lee CJ, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and β-catenin stabilization. Cancer Cell 2009;15:207-19.
14. Loedige I, Filipowicz W. TRIM-NHL proteins take on miRNA regulation. Cell 2009;136:818-20.
15. Deshaies RJ, Joazeiro CAP. RING domain E3 ubiquitin ligases. Ann Rev Biochem 2009;78:399-434.
16. Hammell CM, Lubin I, Boag PR, et al. nhl-2 modulates microRNA activity in Caenorhabditis elegans. Cell 2009;136:926-38.
17. Valiyeva F, Jiang F, Elmaadawi A, et al. Proto-oncogenic activity of a novel TRIM59 gene characterized in mouse cancer models bridging Ras and SV40 Tag oncogene signal pathways. Mol Cancer Ther 2011;10:1229-40.
18. Gabril MY, Onita T, Ji PG, et al. Prostate targeting:PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 2002;9:1589-99.
19. Duan WM, Gabril MY, Moussa M, et al. Knock-in of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate (KIMAP) model demonstrates advantageous features over the transgenic model. Oncogene 2005;24:1510-24.
20. Gabril MY, Duan WM, Wu GJ, et al. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Mol Ther 2005;11:348-62.
21. Van Huizen I, Wu GJ, Moussa M, et al. Establishment of a serum tumor marker for pre-clinical trials of mouse prostate cancer models. Clin Cancer Res 2005;11:7911-19.
22. Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 2004;5:355-66.
23. Xuan JW, Bygrave M, Valiyeva F, et al. Molecular targeted enhanced ultrasound imaging of Flk1 reveals diagnosis and prognosis potential in genetically engineered mouse prostate cancer model. Mol Imaging 2009;8:209-20.
24. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. In: Gloria HSu, ed. Pancreatic cancer: methods and protocols. Totowa, NJ: Human Press, 2005;89-101.
25. Mills SE. Diagnostic surgery pathology. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2010.
26. Wirtzfeld LA, Wu GJ, Bygrave M, et al. Three-dimensional ultrasound micro-imaging for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res 2005;65:6337-45.
27. Xuan JW, Bygrave M, Jiang HY, et al. Functional neo-angiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res 2007;67:2830-9.
28. Imasato Y, Xuan JW, Sakai H, et al. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 2000;164:1819-24.
29. Onita T, Ji PG, Xuan JW, et al. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/ hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 2002;8:471-80.
30. Johnson L, Mercer K, Greenbaum D., et al Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-16.